Literature DB >> 17990062

Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study.

N Klepac1, M Relja, R Klepac, S Hećimović, T Babić, V Trkulja.   

Abstract

BACKGROUND: Animal data and postmortem studies suggest a role of oxidative stress in the Huntington's disease (HD), but in vivo human studies have been scarce. AIM: To assess the presence of oxidative stress in HD patients and its occurrence relative to clinical symptoms.
METHODS: Oxidative stress markers were determined in plasma of HD patients (n = 19), asymptomatic HD gene carriers (with > 38 CAG repeats) (n = 11) and their respective sex and agematched healthy controls (n = 47 and n = 22) in a cross-sectional study.
RESULTS: With adjustment for age and sex, HD patients had higher plasma lipid peroxidation (LP) levels (ratio 1.20, 95% CI 1.09 to 1.32, p < 0.001) and lower reduced glutathione (GSH) levels (ratio 0.72, CI 0.55 to 0.94, p = 0.011) than their age and sex-matched controls. Although considerably younger, HD gene carriers did not differ from HD patients regarding LP and GSH levels, and had higher plasma LP (ratio 1.16, CI 1.02 to 1.32, p = 0.016) and lower GSH than their matched controls (ratio 0.73, CI 0.5 to 1.05). They had higher LP (ratio 1.18, CI 1.02 to 1.34, p = 0.019) and lower GSH (ratio 0.75, CI 0.51 to 1.11) than the healthy subjects matched to HD patients.
CONCLUSIONS: Oxidative stress is more pronounced in HD patients and asymptomatic HD gene carriers than in healthy subjects. Differences in plasma LP and GSH are in line with the brain findings in animal models of HD. Data suggest that oxidative stress occurs before the onset of the HD symptoms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17990062     DOI: 10.1007/s00415-007-0611-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  31 in total

Review 1.  Methods of detection of vascular reactive species: nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite.

Authors:  M M Tarpey; I Fridovich
Journal:  Circ Res       Date:  2001-08-03       Impact factor: 17.367

Review 2.  Huntington's disease genetics.

Authors:  Richard H Myers
Journal:  NeuroRx       Date:  2004-04

Review 3.  Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview.

Authors:  E Mariani; M C Polidori; A Cherubini; P Mecocci
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-09-23       Impact factor: 3.205

4.  Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury.

Authors:  J Christofides; M Bridel; M Egerton; G M Mackay; C M Forrest; N Stoy; L G Darlington; T W Stone
Journal:  J Neurochem       Date:  2006-03-29       Impact factor: 5.372

Review 5.  Antioxidant therapy in neurologic disease.

Authors:  N Delanty; M A Dichter
Journal:  Arch Neurol       Date:  2000-09

Review 6.  Glutamine repeats and neurodegeneration.

Authors:  H Y Zoghbi; H T Orr
Journal:  Annu Rev Neurosci       Date:  2000       Impact factor: 12.449

Review 7.  Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins.

Authors:  D A Butterfield; J Kanski
Journal:  Mech Ageing Dev       Date:  2001-07-15       Impact factor: 5.432

Review 8.  Oxidative stress in Huntington's disease.

Authors:  S E Browne; R J Ferrante; M F Beal
Journal:  Brain Pathol       Date:  1999-01       Impact factor: 6.508

9.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.

Authors:  J Sian; D T Dexter; A J Lees; S Daniel; Y Agid; F Javoy-Agid; P Jenner; C D Marsden
Journal:  Ann Neurol       Date:  1994-09       Impact factor: 10.422

10.  Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease.

Authors:  Pilar del Hoyo; Alberto García-Redondo; Fernando de Bustos; José Antonio Molina; Youssef Sayed; Hortensia Alonso-Navarro; Luis Caballero; Joaquín Arenas; Félix Javier Jiménez-Jiménez
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 4.414

View more
  68 in total

Review 1.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington's disease patients.

Authors:  Miroslav Cuturic; Ruth K Abramson; Robert R Moran; James W Hardin; Elaine M Frank; Andrea A Sellers
Journal:  Neurol Sci       Date:  2013-01       Impact factor: 3.307

3.  Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease.

Authors:  Xueyi Li; Antonio Valencia; Ellen Sapp; Nicholas Masso; Jonathan Alexander; Patrick Reeves; Kimberly B Kegel; Neil Aronin; Marian Difiglia
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

4.  Dysregulation of system xc(-) expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice.

Authors:  Natalie M Frederick; Julie Bertho; Kishan K Patel; Geraldine T Petr; Ekaterina Bakradze; Sylvia B Smith; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2014-07-05       Impact factor: 3.921

5.  Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress.

Authors:  Lisa D Coles; Paul J Tuite; Gülin Öz; Usha R Mishra; Reena V Kartha; Kathleen M Sullivan; James C Cloyd; Melissa Terpstra
Journal:  J Clin Pharmacol       Date:  2017-09-22       Impact factor: 3.126

6.  HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo.

Authors:  Dagmar E Ehrnhoefer; Amber L Southwell; Meenalochani Sivasubramanian; Xiaofan Qiu; Erika B Villanueva; Yuanyun Xie; Sabine Waltl; Lisa Anderson; Anita Fazeli; Lorenzo Casal; Boguslaw Felczak; Michelle Tsang; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2018-01-15       Impact factor: 6.150

Review 7.  Antioxidant gene therapy against neuronal cell death.

Authors:  Juliana Navarro-Yepes; Laura Zavala-Flores; Annadurai Anandhan; Fang Wang; Maciej Skotak; Namas Chandra; Ming Li; Aglaia Pappa; Daniel Martinez-Fong; Luz Maria Del Razo; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Pharmacol Ther       Date:  2013-12-12       Impact factor: 12.310

8.  Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease.

Authors:  Antonio Valencia; Ellen Sapp; Jeffrey S Kimm; Hollis McClory; Patrick B Reeves; Jonathan Alexander; Kwadwo A Ansong; Nicholas Masso; Matthew P Frosch; Kimberly B Kegel; Xueyi Li; Marian DiFiglia
Journal:  Hum Mol Genet       Date:  2012-12-07       Impact factor: 6.150

Review 9.  Ferroptosis, a Recent Defined Form of Critical Cell Death in Neurological Disorders.

Authors:  Jia-Rui Wu; Qing-Zhang Tuo; Peng Lei
Journal:  J Mol Neurosci       Date:  2018-08-25       Impact factor: 3.444

Review 10.  The Emerging Roles of Ferroptosis in Huntington's Disease.

Authors:  Yajing Mi; Xingchun Gao; Hao Xu; Yuanyuan Cui; Yuelin Zhang; Xingchun Gou
Journal:  Neuromolecular Med       Date:  2019-01-02       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.